Trading Cockpit

· checking…
Loading…
← CockpitCompetitor Analysis › VLA.PA Valneva SEOpen in the cockpit ↗

Valneva SEVLA.PACompetitor analysis, valuation and peers

France · EUR·Health Care›Biotechnology
Momentum strong 61
Competitor Analysis ▸ ChartsOpen in the cockpit
Mkt cap
$534M
US dollars, full cap
Free float
82%
of shares outstanding
$/day
$1.03M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-64.0 pp
WACC 9.9%
Hurdle
n/a
no reverse DCF
Next earnings
6 days
12 Nov 2026
Close · EUR€2.50
1D-2.1%
1W+2.0%
1M+0.7%
3M+0.9%
6M-2.5%
YTD-32.7%
1Y-34.9%
ATR %4.4%
52w lowhigh51.4% off high

What Valneva does

Employees: 674

Valneva at a glance

Size Valneva (VLA.PA) is a France Health Care company (Biotechnology) with a market value of $534M, the 172nd largest of 206 France companies the cockpit tracks. Shares closed at €2.50 on 6 Nov 2026.

Performance Over six months the shares fell 2.5%, against -11.3% for the median peer and -0.4% for the France market (cap-weighted) — 6th highest of 18 in its peer set.

Growth Revenue fell 27.2% over the last twelve months (peer median -1.4%); the operating margin is -86.7% (peer median -17.5%).

Valuation It trades at 4.0× enterprise value to sales against a peer median of 9.6× (3rd cheapest of 15).

Capital Return on invested capital runs 64.0 points below its cost of capital (9.9% WACC).

Next results Next results expected around 12 Nov 2026 (exchange calendar; dates can move).

Relative performance

10012011 May 202611 Aug 20266 Nov 2026VLA.PA 101Peer median 88
Six months, rebased to 100: Valneva against the median of its 20 peers (local-currency closes).

Valneva financials

Reported figures in EUR; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue€143M€175M€170M€154M€361M
Revenue growth—+3%+10%-57%—
Gross profit€23.4M€62.7M€63.6M€48.5M€32.0M
EBITDA-€103M-€70.2M-€79.0M-€86.5M-€105M
Net income-€158M-€115M-€12.2M-€101M-€143M
Free cash flow-€87.3M-€86.2M-€98.7M-€228M-€284M
Capital expenditure€2.35M€4.48M€16.4M€14.3M€29.3M
Total debt€210M€207M€216M€209M€152M

Quarterly statements and history in the cockpit →

Valneva competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-40%-20%0%+20%300871688247603255300858300318NGNEDMAC000710115180FTH1789GNFT6586MNPRVLA.PA6-month return →1-month return →
Up and to the right = strong over both horizons. Valneva is the large dot.

Fundamentals: revenue growth against valuation

0%+200%+400%+600%0×2,500×5,000×7,500×30087168824760325596376586VLA.PARevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Valneva is the large dot.

Valneva competitors and peer comparison

How Valneva compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Valneva against its 20 peers (data as of 6 Nov 2026)
MeasureVLA.PAPeer medianRank in peer set
1-month return+0.7%-13.3%4th highest of 21
6-month return-2.5%-11.3%6th highest of 18
Distance from 52-week high-51.4%-43.3%4th lowest of 21
Revenue growth (TTM)-27.2%-1.4%3rd lowest of 14
Operating margin-86.7%-17.5%7th lowest of 15
EV / Sales4.0×9.6×3rd cheapest of 15
ROIC minus cost of capital-64.0 pp-6.5 pp5th lowest of 13

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Valneva VLA.PAFrance$534M-2%-27%-87%4.0×n/an/a
Hvsen Biotechnology 300871.SZChina$531M-33%+2%17%2.2×n/an/a
Sinotherapeutics 688247.SSChina$537M-14%-17%0%7.0×31.6%+7.0%
Liaoning Dingjide Petrochemical 603255.SSChina$530M-15%+70%5%5.4×n/an/a
Beijing Scitop Bio-Tech 300858.SZChina$526M-25%+4%8%8.0×n/an/a
Beijing Bohui Innovation Biotechnology 300318.SZChina$553M-19%+6%-11%6.5×n/an/a
LongBio Pharma (Suzhou) 1779.HKHong Kong$554Mn/an/an/an/an/an/a
HanchorBio 7827.TWTaiwan$511Mn/an/a-225%48.0×n/an/a
Shanghai Serum Bio-Technology 688163.SSChina$507M-11%-1%26%13.7×n/an/a
Neurogene NGNEUnited States$506M-18%-100%n/an/an/an/a
DiaMedica Therapeutics DMACUnited States$505M+48%n/an/an/an/an/a
Berry Genomics 000710.SZChina$504M-5%-2%-24%3.8×n/an/a
Qurient 115180.KSSouth Korea$503M-59%-20%-517%98.9×n/an/a
Crescent Biopharma CBIOUnited States$503M-28%n/a-1,418%28.3×n/an/a
Faeth Therapeutics FTHUnited States$570M-6%n/an/an/an/an/a
Alebund Pharmaceuticals (Jiangsu) 9637.HKHong Kong$576Mn/a+674%-495%25.7×n/an/a
Climb Bio CLYMUnited States$591M-10%n/an/an/an/an/a
Scinopharm Taiwan 1789.TWTaiwan$482M-1%-5%-4%5.2×15.2%+0.5%
Genfit GNFT.PAFrance$593M+19%+28%-130%11.2×40.0%+143.5%
CHO Pharma 6586.TWOTaiwan$480M+57%-47%-17,694%8,168.1×n/an/a
Monopar Therapeutics MNPRUnited States$479M+12%n/an/an/an/an/a

Questions

Which companies are Valneva's closest peers?
The cockpit's peer set: Hvsen Biotechnology (300871.SZ), Sinotherapeutics (688247.SS), Liaoning Dingjide Petrochemical (603255.SS), Beijing Scitop Bio-Tech (300858.SZ), Beijing Bohui Innovation Biotechnology (300318.SZ), LongBio Pharma (Suzhou) (1779.HK), HanchorBio (7827.TW), Shanghai Serum Bio-Technology (688163.SS).
Is Valneva expensive compared with its peers?
On ev / sales it trades at 4.0× against a peer median of 9.6×, 3rd cheapest of 15 in its peer set.
How has Valneva stock performed?
Over six months to 6 Nov 2026 the shares returned -2.5% against -11.3% for the median peer; over one year -34.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.